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Objective: Femoropopliteal bypass still is the standard surgical therapy for disabling claudication and critical ischemia.
When autologous vein is not suitable synthetic or biological prostheses may be considered. Second generation glutaral-
dehyde tanned human umbilical vein (HUV) graft was chosen for above and below knee femoropopliteal bypass when
autologous vein was not available. A single center experience regarding long-term graft function, secondary reinterven-
tions, and potential biodegeneration of the HUV is presented.
Methods: Between January 1994 and January 2005, 211 consecutive femoropopliteal bypass operations with HUV (65
above knee and 146 below knee) were performed in 197 patients for disabling claudication (57), chronic critical ischemia
(130), popliteal artery aneurysm (9), acute ischemia (14), or aneurysmal degeneration of a synthetic graft (1) in the
absence of suitable ipsilateral great saphenous vein. Grafts were followed with duplex scan supplemented by additional
angiography in case of recurrent ischemia with prospective documentation of follow-up data in a computerized vascular
database. Surveillance of the HUV included routine evaluation of potential biodegeneration with duplex scan. Retro-
spective analysis of graft patency, limb salvage, and signs of aneurysmal degeneration was performed.
Results: Mean (median) follow-up was 44 (35) months (range 1 to 143 months). Thirty-day mortality was 2.4%. Early
postoperative bypass thrombosis after a median of 4 days postoperatively (0 to 30 days) prompted revision with
thrombectomy in 16% of cases. Besides late bypass thrombosis in 14.7%, additional operative or endovascular reinter-
ventions during follow-up to maintain or restore graft patency was necessary in 8.5% of bypasses. Primary, primary
assisted, secondary patency rate, and limb salvage rate after 5 years were 54%, 63%, 76%, and 92%, respectively, for all
bypasses with no significant difference between above and below knee anastomosis. Duplex scan identified segmental
aneurysmal degeneration in six grafts, which led to operative reintervention in three cases. The rate of detected aneurysm
for grafts patent for more than three years was 7% with a rate of reintervention for aneurysm of 3.5%.
Conclusion: Although a considerable rate of early thrombotic occlusions occurred, excellent secondary graft patency and
limb salvage combined with a tolerable rate of late aneurysmal degeneration detected bymeans of duplex scan surveillance
justify the use of the HUV in femoropopliteal bypass surgery when ipsilateral autogenous vein is not suitable. ( J Vasc
Surg 2007;46:280-8.)Small caliber biological or synthetic vascular prostheses
are used in peripheral bypass surgery when autologous vein
is limited due to insufficient caliber, varicose or inflamma-
tory changes, or previous harvest. Although there is suffi-
cient evidence that good quality saphenous vein must be
considered as the best graft material for all infrainguinal
bypasses, some surgeons still prefer synthetic grafts in above
knee (ak) femoropopliteal bypass. The glutaraldehyde
tanned human umbilical vein (HUV) supported by an
external polyester mesh was successfully introduced as small
caliber vascular conduit of biological origin in infrainguinal
bypass surgery by Dardik almost three decades ago.1,2
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280First clinical series, with above and below knee first
generation HUV femoropopliteal bypass, provided prom-
ising patency rates compared with the available polytetra-
fluoroethylene (PTFE) grafts at that time.3-5 But soon after
the introduction of this graft into clinical routine, a disap-
pointing tendency for early postoperative graft thrombosis
or wall dissection6,7 and the formation of graft aneurysms
caused by biodegradation of the umbilical vein wall were
reported.8-10 This stopped the initial enthusiasm and led to
reluctance amongmost vascular surgeons regarding the use
of first generation HUV. The modified HUV graft, with a
reinforced external mesh (Bio-Vascular Inc, St Paul Minn;
since May 2002 renamed into Synovis Life Technologies,
Inc, St Paul, Minn), has been available for almost two
decades. Influenced by promising clinical reports in regards
of patency and biological behavior,11,12 this modified
HUV graft was chosen as the sole prosthetic graft when
ipsilateral autologous vein was inadequate or absent in
femoropopliteal bypass surgery. The results of a single
center consecutive series of above and below knee femoro-
popliteal bypass with second generation HUV-grafts were
analyzed.
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From a total of 2046 infrainguinal bypass operations
performed between January 1994 and December 2004, all
femoropopliteal HUV bypasses documented in a comput-
erized vascular database were identified. All patients with
HUV grafts were enrolled in a follow-up scheme postoper-
atively and data subsequently entered prospectively in a
computerized database. Patient characteristics and periop-
erative and follow-up data were evaluated in a retrospective
analysis.
Operative technique. At the authors’ institution, ip-
silateral great saphenous vein is considered graft of first
choice for above and below knee femoropopliteal bypass.
PTFE grafts were not used during the study period. HUV
grafts were only considered if either the great saphenous
vein was already harvested, or intraoperative exploration
and assessment proved the vein unsuitable for bypass con-
struction. Contralateral saphenous vein was not routinely
considered as a primary alternative.
The HUV graft was chosen appropriate to the size of
the recipient popliteal artery with a diameter of either 5 or
6 mm and was rinsed prior to implantation with 1 liter of
dextrane solution according to the manufacturers’ rinsing
protocol followed by instillation of heparin solution
(25000 IU) into the prosthesis, which was flushed out prior
to the first anastomosis. The arteriotomy of the recipient
popliteal artery was extended to a length of 20 to 25 mm,
and anastomoses were constructed with polypropylene su-
ture in a conventional manner with routine intravenous
administration of 5000 IU heparin. For the proximal anas-
tomosis, the common femoral artery was preferred and
additional endarterectomy or profundaplasty performed if
necessary. Grafts were passed through the leg in a subfascial
layer using a hollow plastic sheath tunneling device as
gently as possible trying to avoid any traction or reposition-
ing. For the same reason, use of vascular clamps on the
HUV was strictly avoided and control obtained with soft
bulldog clamps. Protamin was not used routinely. In early
postoperative revision, thrombectomy catheters were
avoided whenever possible to minimize the potential risk of
injury to the smooth inner surface of theHUV. The throm-
bus was removed either by means of direct extraction,
gentle milking of the graft, or by flushing it with heparin-
ized saline solution with routine revision of both anasto-
moses.
Graft patency was confirmed intraoperatively with tran-
sit time flow measurement (Cardio-Med Medi-Stim, Oslo,
Norway; Transonic Systems, Ithaca, NY) and by additional
postoperative duplex scan and/or angiography prior to
discharge. Postoperative intravenous administration of
heparin was started with 500 IU/h, and the dose subse-
quently increased intending doubling of partial thrombo-
plastin time (PTT) after the second postoperative day.
Most patients (n  173) received additional temporary
combined administration of antiplatelet medication (Aspi-
rin  Tyklid or Aspirin  Plavix) starting with the day of
operation. Oral anticoagulation with the vitamin K antag-onist phenprocoumon (Marcumar) was the preferred long-
term antithrombotic therapy and started within a few days
postoperatively. Heparin and antiplatelet medication were
discontinued when the international normalized ratio
(INR) reached therapeutic range. Oral anticoagulation at a
level of 2.5 was continued indefinitely under supervision of
the attending general practitioner with regular INR control
blood tests. Long-term antiplatelet medication was only
started in presence of contraindications for oral anticoagu-
lation, bleeding complications, or poor patient compliance
at a later date.
A follow-up schemewith visits after 3, 6, 12, 18, and 24
months with annual repetitions thereafter was started. The
HUV was examined with duplex scan to detect changes
related to possible biodegeneration. The complete length
of the graft and the inflow and outflow arteries were exam-
ined with duplex. A peak velocity above 2 m/s was consid-
ered as pathologic and angiography initiated if deemed
necessary. The inner and outer diameters were measured,
and the wall thickness assessed. A maximal outer graft
diameter of more than 16 mm was defined as aneurysm,
and a diameter between 10 and 16 mm as dilatation. A
bypass was assessed as patent according to the recom-
mended standards for reports dealing with lower extremity
ischemia.13 When graft replacement or major amputation,
despite a patent prosthesis, was necessary for aneurysmal
degeneration or late infection of a patent HUV for statisti-
cal analysis, this was considered as graft failure. All follow-
up data were prospectively entered in a computerized data
base (ACCESS 2000 for windows) and retrospectively an-
alyzed (SPSS 14.0 for windows) using Kaplan Meyer sur-
vival test and log rank test according to the regulations for
clinical studies of the ethics committee of the state of
Rhineland-Palatinate, Germany.
RESULTS
Patients, risk factors, and indication for operation.
Sixty-five above knee and 146 below knee femoropopliteal
bypasses were performed over an 11-year period in 197
patients in 208 lower limbs. Eleven patients underwent
staged or simultaneous bilateral operations, and three legs
were reoperated using the same type of graft in femoropop-
liteal position. Patient characteristics, risk factors, indica-
tions for surgery, and previous ipsilateral operations, inter-
ventions, and inflow procedures are listed in Tables I, II,
and III.
The ipsilateral great saphenous vein was previously
harvested for coronary bypass or lower extremity arterial
reconstruction in 74 patients (35.1%) or stripped in 17
patients (8.1%). In all other situations, the dissected vein
was not suitable due to insufficient caliber of less than 3.5
mm, inflammatory changes, and extensive varicose degen-
eration.
Patient related outcome. Five patients (2.4%), one
patient after emergency bilateral operation, died within 30
days postoperatively from fatal cardiac events or sepsis; all
five patients were operated either for acute ischemia or
chronic critical ischemia. There was no perioperative mor-
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teal aneurysm. Early postoperative complications are listed
in Table III. One patient was lost to follow-up after 49
months, and 81 patients died during follow-up, 65 of them
with patent bypass(es) and free of ischemic symptoms. Over
all, patient survival was 53% and 34%, at 5 and 10 years
postoperatively. Long-term oral anticoagulation was initi-
ated in 182 instances. In all other cases, antiplatelet therapy
was started. Subsequently phenprocoumon (Marcumar)
was discontinued in 39 of the 182 cases (21%), generally for
poor compliance or tumor.
Graft function and limb salvage. Early postoperative
complete or partial bypass thrombosis was noted in 36
bypasses (17.1%). The incidence of early postoperative
thrombosis decreased with time and gain of experience
with the HUV-graft and after introduction of additional
early postoperative antiplatelet therapy. It dropped from
38.7% in 1994-1995 to 8.3% in 2002-2004. Interventions
for early bypass occlusion and outcomes are listed in Table
IV. Six legs with critical ischemia or severe acute ischemia
underwent early major amputation, in one instance without
revision of the thrombosed graft, in three cases after a failed
thrombectomy, and in one case for progressive foot gan-
grene despite a successfully revised ak bypass.
Follow-up with repetitive duplex investigations was
available in 177 of the implanted 211 prostheses (84%).
Besides those patients with irreversible early HUV failure,
Table I. Patient demographics
Patients n  197 %
Age 70.0 /8.7
50.6-93.6
Female 78 39.6
Male 119 60.4
Hypertension 161 81.7
Hyperlipidemia 133 67.5
Diabetes 95 48.2
Smoking 112 56.8
ESRD 11 5.6
CAD 109 55.3
CVA 28 14.2
ESRD, End stage renal disease; CAD, coronary artery disease; CVA, cere-
brovascular accident.
Table II. Indications for bypass surgery
Indication n %
Severe disabling claudication 57 27.0
Critical limb ischemia 130 61.6
Rest pain 47 22.3
Necrosis/ulceration 83 39.3
Popliteal artery aneurysm 9 4.3
Acute ischemia 14 6.6
Synthetic graft aneurysm* 1 0.5
Total 211 100
*14-year-old above knee femoropopliteal Dacron bypass with massive an-
eurysmal degenerationscheduled duplex could not be performed because of rapidgeneral deterioration, early death within 12 months, and
poor patient compliance. Thirty-one bypasses (14.7%)
failed during follow-up from which occlusion was diag-
nosed at the time of routine duplex in 15 grafts (7.2%).
Duplex scan unmasked significant lesions necessitating ad-
ditional interventions to maintain graft patency in 18 grafts
(8.5%). Despite of prophylactic intervention one below
knee (bk) bypass occluded with need of further unsuccess-
ful thrombectomies. All together, in 27 bypasses (12.8%)
during follow-up, 31 further reoperations or interventions
were necessary to maintain or restore patency. Modes of
graft failures and specific treatments are outlined in detail in
Table IV.
During follow-up, major amputation after bypass oc-
clusion was necessary in seven instances. None of these
patients was initially operated for claudication or popliteal
aneurysm. Primary, primary assisted, secondary patency,
and limb salvage using Kaplan-Meier analysis were 54%,
63%, 76%, and 92%, respectively, at 5 years (see Figs 1 to 4).
No significant differences in primary (P  .502), primary
assisted (P  .265) and secondary patency (P  .978), or
limb salvage (P  .993) were found for above or below
knee bypass.
Biodegradation of the HUV graft. Duplex scan de-
tected biodegradation in 13 bypasses (Table V). Seven
bypasses exhibited diffuse or segmental thickening of the
graft wall. In two cases, endovascular or surgical interven-
tion was initiated. Five grafts remained patent without any
intervention. Aneurysmal degeneration with a mean maxi-
mal diameter of 21 (13 to 31mm) was detected in six grafts
after a mean of 69 (40 to 106 months) among 84 HUVs
being patent 36 months or more (7%). Three of them were
Table III. Early and late patient outcome
Postoperative (30 days) complications
211
operations* %
Death (congestive heart failure, sepsis)* 5 2.4
MI, cardiac failure, arrhythmia 18 8.5
Stroke 2 0.9
Respiratory failure, pneumonia 6 2.8
Renal failure 1 0.5
Sepsis, systemic inflammatory signs 6 2.8
Delirium 6 2.8
Others 11 5.2
Combined mortality and morbidity 34† 16.1
Hematoma (surgical revision) 21 (5) 10.0 (2.4)
Wound infection/delayed wound
healing 20 9.5
Amputation 6 2.9
Late patient outcome mean follow-up
33.6 months (1-143 months)
Death (cardiovascular, tumor) 82 41.6
5-year survival (Kaplan-Meier) 53.1
Amputation (4 - 86 months) 7 3.4
MI, Myocardial infarction.
*One patient died after staged bilateral emergency operation; total mortality
5/211 operations (2.4%).
†39 severe systemic vascular and nonvascular complications in 34 patients.replaced with either a new HUV or saphenous vein, twice
.9
JOURNAL OF VASCULAR SURGERY
Volume 46, Number 2 Neufang et al 283on an elective basis. Two grafts were found to be dilated
with unimpaired clinical function and are under duplex
surveillance at the date of this report. One patient with a
significant aneurysmal degeneration died from unrelated
cause with a patent graft.
DISCUSSION
Durable relief of ischemic symptoms without addi-
Table IV. Early and late graft failure and underlying path
Early graft failure (30 days) n
% g
aff
Complete graft occlusion or intraluminal thrombus 36 1
Operative revision performed 35 1
Thrombectomy alone* 29 1
Thrombectomy, patch angioplasty dis.
Anastomosis 4
Thrombectomy, extension to tibial artery 1
New bypass without thrombectomy 1
Failed revision: new bypass ( contralateral vein;
HUV) 2
Conservative treatment 1
Major amputation 4
Death before further intervention 1
Major amputation without revision 1
Graft infection after successful early revision;
preservation after Local debridement and long
term antibiotic therapy 2
Late thrombotic graft failures and additional
interventions or operations to maintain patency n
% g
affe
Late bypass thrombosis 31 14
Thrombosis with unclear reason (confirmation
with duplex or angiogram) 10 4
Conservative treatment 5 2
Thrombectomy 0 0
New bypass 3 1
Amputation 2 0
Thrombosis due to identified stenosis (inflow/
outflow) 4 1
Thrombectomy  inflow reconstruction 1 0
Thrombectomy  patch distal anastomosis 1 0
Thrombectomy  extension 1 0
New bypass 1 0
Thrombosis due to graft stenosis (wall thickening) 1 0
Thrombectomy; re-thrombectomy, new bypass 1
Thrombosis after discontinuation of
anticoagulation (diagnostic) 11(4) 5
Conservative treatment 3 1
Thrombectomy 3 1
Thrombectomy  patchplasty (stenosis) 1 0
Thrombectomy  extension 1 0
New bypass 1 0
Amputation 2 0
Acute thrombosis with anticoagulation 2 0
Thrombectomy 2
Thrombosis due to late graft infection 2 0
Replacement with autologous veins (success) 2
Thrombosis due to dilation (aneurysm) (new
bypass) 1 0
Patent graft abandoned for infection (new bypass) 1 0
Patent graft abandoned for dilation (new bypass) 2 0tional risk of amputation in case of bypass occlusion andlong-term limb salvage in case of critical ischemia must be
the primary goal of infrainguinal bypass operations.
Role of bypass graft material in femoropopliteal
bypass. Recent long-term results from controlled studies
for above knee bypass and historical results for below knee
bypass procedures regarding graft patency clearly support
preferential use of saphenous vein whenever possible.14,15
Some authors recommend the use of arm veins and spliced
in 211 HUV grafts; modes of treatment and success
Time to
failure (d)
Patency
restored
Patency
not restored
Late failure despite
initial success
4 (0-30)
26 8 3
0-15 21 8 3
0-5 4 0 0
6 1 0 0
30 0 1 0
2 0 1 0
2 0 0
Time to failure
(months)
Patency
maintained/
restored
Patency not
restored
Late failure despite
initial success
36 (1,5-69) 11 20 3
12.6 (2-34) 0 10 0
3,7,12,12,27 0 0 0
- 0 0 0
2, 4, 23 0 0 0
2, 34 0 0 0
2-69 3 1 2
6 1 0 1
2 1 0 1
69 1 0 0
45 0 1 0
60 1 0 1
60, 65, 75
22 (3-56) 5 6 0
12,32,36 0 3 0
3,3,5 3 0 0
30 1 0 0
21 1 0 0
20 0 1 0
23,56 0 2 0
1,5; 13 2 0 0
1,5; 13 0 2 0
56 0 1 0
44 0 1 0
90, 101 0 2 0ology
rafts
ected
7.1
6.6
3.7
1.9
0.5
0.5
0.9
0.5
1.9
0.5
0.5
0.9
rafts
cted
.7
.7
.3
.4
.9
.9
.5
.5
.5
.5
.5
.2
.4
.4
.5
.5
.5
.9
.9
.9
.5
.5grafts before synthetic grafts are considered for implanta-
n
despit
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surgeons still use a synthetic conduit as first choice graft in
ak position even when autologous vein is available. Disap-
pointing results in above knee synthetic bypass for re-do
procedures after bypass graft occlusion have been reported
especially after operations performed for intermittent clau-
dication with poor patency after bypass thrombectomy and
a significant risk of subsequent amputation.17 However, as
vein is not always available, there is still a substantial need
for a prosthetic alternative if limb perfusion has to be
improved by means of surgery. Thus biological vascular
conduits like the glutaraldehyde tanned human umbilical
Table IV. Continued
Late thrombotic graft failures and additional
interventions or operations to maintain patency n
% g
affe
Treatment to prevent failure of patent graft
(duplex diagnosis of severe pathology)* 18 8
Stenosis proximal anastomosis† 10 4
Patchplasty 10
Stenosis HUV graft (wall thickening) 1 0
PTA 1
Stenosis distal anastomosis 4 1
Patchplasty‡ 3 1
PTA anastomosis 1 0
Stenosis of outflow vessel 3 1
Bypass graft extension§ 2
PTA outflow vessel 1
HUV, Human umbilical vein; PTA, percutaneous transluminal angioplasty
*Five grafts in addition successfully treated for early (4) or late (1) thrombo
†One later thrombosis due to graft stenosis with consecutive replacement b
‡One later restenosis with subsequent partial replacement and graft extensio
§One later failure due to development of aneurysm with graft replacement
Fig 1. Primary patency in 65 above knee and 146 below knee
femoropopliteal bypasses with second generation HUV.vein may be considered. Although data from randomizedtrials comparing PTFE and HUV in above knee femoro-
popliteal bypass demonstrated superior patency for the
HUV, not much published experience is available during
the last decade.18-22 Aalders reported an excellent 6-year
secondary patency of 76.4% for the HUV in contrast to
51.4% for PTFE in a randomized trial in 96 patients oper-
ated mainly for claudication and maintained on coumadin
therapy.19 Interestingly, he found a higher increase of
ischemic symptoms after occlusion of a PTFE graft com-
pared with the failed HUV grafts.19 This reported low rate
of significant recurrent ischemia correlates well with our
own observations. In none of the patients operated for
Time to failure
(months)
Patency
maintained/
restored
Patency not
restored
Late failure despite
initial success
28 (4-96) 18 0 4
32 (6-96) 10 0 1
10 0 1
36 1 0 0
36
7,9,30,33 4 0 0
9,30,33 3 0 0
7 1 0 0
4,13,64 3 0 1
4,64 2 0 1
13 1 0 0
bypass
e unimpaired patency
Fig 2. Primary assisted patency in 65 above knee and 146 below
knee femoropopliteal bypasses with second generation HUV.rafts
cted
.5
.7
.5
.9
.4
.5
.4
.
sis
y newclaudication, a deterioration of symptoms was noted. John-
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tency for ak bypass of 53% for HUV after 5 years ranging
between saphenous vein (73%) and PTFE (39%).18 Accord-
ing to our observation, he experienced a rather high early
failure rate for HUV compared with saphenous vein or
PTFE.
Only few historical data comparing PTFE and HUV in
below knee bypass exist, but they indicated a superior
performance for HUV. 23,24 The most extensive experience
with the HUV was reported by Dardik. From 1975 until
Fig 3. Secondary patency in 65 above knee and 146 below knee
femoropopliteal bypasses with second generation HUV.
Fig 4. Limb salvage in 65 above knee and 146 below knee
femoropopliteal bypasses with second generation HUV.1999, the HUV was implanted in 1275 cases by hisgroup.20,25 In his recent series, a 5-year secondary patency
of 71% is reported for all grafts preferring coumadin ther-
apy. This is almost identical to our results with preference of
long-term oral anticoagulation and supports our attitude
towards the need of a rather aggressive long-term anti-
thrombotic management for this conduit. Most historical
series for below knee popliteal PTFE bypass indicated
rather disappointing patency rates,26 but on the other
hand, the use of an interposition vein cuff at the distal
anastomosis has improved results for primary below knee
bypass with a patency of 57% after 3 years.27,28 In addition,
Deutsch et al provided favorable results with endothelial
seeded bk PTFE grafts with a 5-year patency of 76% in 76
patients.29 Contrary to historical series, promising results
for below knee bypass were reported with heparin-bonded
grafts from a nonrandomized multicenter trial with a sec-
ondary patency of 87.8% after 24 months.30,31 Therefore,
the role of synthetic grafts may possibly be redefined in the
future.
Although there is a strong tendency to treat the super-
ficial femoral artery with endovascular procedures, our ac-
tual long-term results with a late patency of more than 70%
after 5 years appear favorable compared with those obtain-
able with recent series of endovascular procedures like
subintimal angioplasty or stenting of the superficial femoral
artery.32-34
Early bypass thrombosis and late reintervention.
The rate of early postoperative graft thrombosis, especially
in the first years after introduction of the HUV at our
institution, was responsible for the majority of secondary
interventions. This is clearly disappointing but this rate
could be lowered by adaptation of surgical technique and
probably by use of additional early postoperative anti-
thrombotic therapy with combined antiplatelet medica-
tion, although this was not proven by means of a trial. The
tendency for this early graft thrombosis may be attributed
to previously-documented increased thrombocyte accumu-
lation on the grafts inner surface demonstrated historically
in perfusion models.7,35
Contrary to this, the rate of late reoperations for acute
recurrent ischemia due to acute bypass thrombosis in our
series was surprisingly low. All in all, acute reintervention
was necessary in 12 grafts (5.7%), in four cases with a redo
bypass. The majority of late reinterventions was initiated
after regular follow-up had detected significant stenosis or
deterioration of run-off indicating a high risk of bypass
occlusion. These prophylactic repairs probably contribute
to the excellent secondary long-term patency.
Risk of subsequent amputation. Amputation after
bypass occlusion was only necessary when surgery was
performed for critical ischemia or severe acute ischemia.
None of the limbs operated for claudication or popliteal
aneurysm had to be amputated after graft failure. This is
similar to the previously reported lower risk for amputation
after failed vein bypass.36
Problem of biodegradation. Historical reports of a
high incidence of biodegradation leading to formation of
graft aneurysms and the fear for late secondary interven-
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of the HUV graft might explain the reluctance among the
vascular community regarding its use.6,8-10 Biodegradation
was attributed to a failure in crosslinking of the collagen
molecules during the tanning procedure and to the impact
of circulating proteolytic enzymes.37 Hasson reported a
rate of 57% for aneurysmal degeneration in grafts patent for
more than 24 months. Besides local wall dissection and
intramural formation of hematoma, he described giant cell
reaction in the diseased graft segments.38 Karkow and
other investigators explained aneurysmal degeneration in
first generation HUV besides local destruction of the graft
wall itself with the loosely knitted and weak external Da-
cron mesh and even found local mesh destruction.39,40
Sommeling, investigating the original HUV grafts with
duplex scan, reported a rate of 37% aneurysmal degenera-
tion with a mean diameter of 12.6 mm but a need of graft
removal only in two cases with large aneurysms and recom-
mended a reluctant policy of further thorough duplex
surveillance.41
Aalders found aneurysmal changes in 30% of patent
HUV grafts after a mean follow-up of 78 months necessi-
tating surgical intervention in one case.19 The only avail-
able data on possible biodegradation of the modified HUV
consist of a series of 105 femoropopliteal bypasses operated
since 1986.21 Aneurysmal dilatation was detected in 17%
using duplex scan demonstrating local destruction of the
graft wall in two cases. An early postoperative increase in
graft diameter of up to 9 to 10 mm was attributed to the
higher elasticity of the graft and surveillance of the HUV
with duplex recommended.21
In our reported series of 211 popliteal bypasses, aneu-
rysm formation could be demonstrated in six grafts after a
mean of 69 (42 to110 months) necessitating operative
graft replacement in three cases. The observed increase in
wall thickness in seven cases may be explained by formation
of intramural hematoma with subsequent stabilization or
Table V. Biodegeneration in 177 HUV grafts followed w
Pathological changes of HUV
graft and mode of intervention n %
Max. diameter
mm
(aneurysm)
Increase in HUV wall thickness/
graft stenosis 7 3.9
2
PTA 1 3
Replacement 1 6
Surveillance 5 2
Dilation (Aneurysm diameter
16 mm) in grafts patent 
36 months (n  84) 6 7
13, 17, 18,
24, 25, 31
4
Symptoms 2* 24, 25
replacement 3 3.5 24, 25, 31 5
Surveillance 3 13, 17, 18 4
HUV, Human umbilical vein; PTA, percutaneous transluminal angioplasty
*Acute bypass thrombosis; local tenderness; both grafts replaced.resorption.6 The positive long-term outcome after success-ful PTA of a significantmidgraft stenosis could be explained
by compression and remodeling of this local intramural
hematoma with balloon angioplasty. However, the role of
these changes in wall thickness in regards of graft function
remains unclear. All in all, comparing the potential for
biodegeneration of the HUV with its performance as a
vascular conduit according to our experience this negative
feature to us appeared to be tolerable.
CONCLUSION
Although the modified HUV is still more complicated
in handling than conventional synthetic grafts and exhibits
a tendency for early graft thrombosis, these features may
become counterbalanced by its performance as a durable
small caliber conduit. Excellent late HUV patency rates, in
combination with a tolerable rate of clinically relevant
biodegradation, justify the persistent role of this type of
biological graft in lower extremity bypass. Its possible struc-
tural changes that remind to those less frequently detected
in very old autologous vein grafts should be a reason for
further prospective investigation and redefining the role of
biological grafts in femoropopliteal bypass. As in the future,
vascular surgery will have to deal with an increasing number
of infrainguinal reconstructions in an aging population
durable long-term relief of ischemic symptoms with a low
late reintervention rate when autologous vein is not avail-
able will become more important. From our point of view,
a detectable but tolerable tendency for biodegradation may
be neglected especially in older patients with critical isch-
emia and limited life expectancy in favor of an undisturbed
long-term graft function.
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